Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Phillip Dennis, Vice President, Lung Cancer and CEACAM Global Project Head, Sanofi

Advertisement

Articles by Phillip Dennis, Vice President, Lung Cancer and CEACAM Global Project Head, Sanofi

Responding to Resistance in Lung Cancer

ByPhillip Dennis, Vice President, Lung Cancer and CEACAM Global Project Head, Sanofi
October 25th 2023
Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on OncLive

    1

    FDA Grants Breakthrough Therapy Designation to Olomorasib in KRAS G12C+ Pancreatic Cancer

    2

    FDA Grants Orphan Drug Designation to Zocilurtatug Pelitecan for Neuroendocrine Carcinomas

    3

    Sapablursen Represents Potential Avenue for Improved Hepcidin Production in Polycythemia Vera

    4

    NCCN Guidelines Add Gedatolisib-Based Regimens for Pretreated PIK3CA Wild-Type Advanced Breast Cancer

    5

    Mayo Clinic–Led Study Finds No Improvement in Overall Survival From Longer Multiple Myeloma Maintenance Therapy

    • Advertise
    • About OncLive
    • Editorial Board
    • MJH Life Sciences brands
    • Contact Us
    • Privacy
    • Terms & Conditions
    • Do Not Sell My Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo
    Download on Apple
    Download on Google Play

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us